CO2018005715A2 - Derivados de indol n-sustituidos como moduladores de los receptores de pge2 - Google Patents

Derivados de indol n-sustituidos como moduladores de los receptores de pge2

Info

Publication number
CO2018005715A2
CO2018005715A2 CONC2018/0005715A CO2018005715A CO2018005715A2 CO 2018005715 A2 CO2018005715 A2 CO 2018005715A2 CO 2018005715 A CO2018005715 A CO 2018005715A CO 2018005715 A2 CO2018005715 A2 CO 2018005715A2
Authority
CO
Colombia
Prior art keywords
modulators
indole derivatives
substituted indole
pge2 receptors
receptors
Prior art date
Application number
CONC2018/0005715A
Other languages
English (en)
Inventor
Isabelle Lyothier
Julien Pothier
Sylvia Richard-Bildstein
Thierry Sifferlen
Peters Lorenza Wyder
Davide Pozzi
Olivier Corminboeuf
Heinz Fretz
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CO2018005715A2 publication Critical patent/CO2018005715A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a derivados de la fórmula (I), en donde (R1)n, R2, R3, R4a, R4b, R5a, R5b y Ar1 son como se describen en la descripción, a su preparación, a sales farmacéuticamente aceptables de los mismos, y a su uso como productos farmacéuticos, a composiciones farmacéuticas que contienen uno o más compuestos de la fórmula (I) y en especial a su uso como moduladores de los receptores de prostaglandina 2: EP2 y/o EP4.
CONC2018/0005715A 2015-11-20 2018-05-30 Derivados de indol n-sustituidos como moduladores de los receptores de pge2 CO2018005715A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2015077269 2015-11-20
PCT/EP2016/078028 WO2017085198A1 (en) 2015-11-20 2016-11-17 N-substituted indole derivatives as pge2 receptor modulators

Publications (1)

Publication Number Publication Date
CO2018005715A2 true CO2018005715A2 (es) 2018-07-10

Family

ID=57326428

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0005715A CO2018005715A2 (es) 2015-11-20 2018-05-30 Derivados de indol n-sustituidos como moduladores de los receptores de pge2

Country Status (33)

Country Link
US (2) US11241431B2 (es)
EP (2) EP3928836A1 (es)
JP (2) JP2018534328A (es)
KR (1) KR102352022B1 (es)
CN (1) CN108349949B (es)
AU (1) AU2016358242B2 (es)
BR (1) BR112018010291B1 (es)
CA (1) CA3002610C (es)
CL (1) CL2018001325A1 (es)
CO (1) CO2018005715A2 (es)
CR (1) CR20180323A (es)
CY (1) CY1124913T1 (es)
DK (1) DK3377483T3 (es)
EA (1) EA037953B1 (es)
ES (1) ES2897954T3 (es)
HR (1) HRP20211678T1 (es)
HU (1) HUE056679T2 (es)
IL (1) IL259424B (es)
LT (1) LT3377483T (es)
MA (2) MA55046A (es)
MX (1) MX2018005268A (es)
MY (1) MY195888A (es)
PE (1) PE20181304A1 (es)
PH (1) PH12018501077A1 (es)
PL (1) PL3377483T3 (es)
PT (1) PT3377483T (es)
RS (1) RS62598B1 (es)
SA (1) SA518391588B1 (es)
SG (1) SG11201803627XA (es)
SI (1) SI3377483T1 (es)
TW (2) TWI754397B (es)
UA (1) UA123441C2 (es)
WO (1) WO2017085198A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018210987A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
CA3063788A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
DK3625228T3 (da) 2017-05-18 2021-10-11 Idorsia Pharmaceuticals Ltd Pyrimidinderivater som pge2-receptormodulatorer
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
CN109678780A (zh) * 2017-10-19 2019-04-26 中国石油化工股份有限公司 一种制备3-烷基吲哚衍生物的方法
US11547712B2 (en) 2017-11-20 2023-01-10 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US11788064B2 (en) 2018-01-05 2023-10-17 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
CN112135613A (zh) 2018-03-20 2020-12-25 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
US20220064146A1 (en) * 2018-12-31 2022-03-03 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
EP3693359A1 (en) * 2019-02-08 2020-08-12 Medibiofarma, S.L. New n-benzyl-2-phenoxybenzamide derivatives as prostaglandin e2 (pge2) receptors modulators
WO2021060281A1 (ja) * 2019-09-24 2021-04-01 Ａｇｃ株式会社 プロスタグランジンｅ２レセプターｅｐ２／ｅｐ４デュアルアンタゴニスト
JPWO2022102731A1 (es) 2020-11-13 2022-05-19

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
ATE395058T1 (de) 2000-03-24 2008-05-15 Asterand Uk Ltd Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
AU2003216581A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
WO2003086390A1 (en) 2002-04-12 2003-10-23 Pfizer Japan Inc. Imidazole compounds as anti-inflammatory and analgesic agents
CN1662551A (zh) 2002-05-23 2005-08-31 瑟瑞技术公司 前列腺素e2受体亚型ep4的拮抗肽
ES2308139T3 (es) 2003-01-29 2008-12-01 Asterand Uk Limited Antagonista de receptos ep4.
CN1871240B (zh) 2003-08-26 2012-11-07 帝人制药株式会社 吡咯并嘧啶酮衍生物
WO2005021508A1 (en) 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
EP1756043B1 (en) 2004-05-04 2009-07-01 RaQualia Pharma Inc Ortho substituted aryl or heteroaryl amide compounds
CA2565813C (en) 2004-05-04 2010-10-26 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
GT200500284A (es) * 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
AU2006246930C1 (en) 2005-05-19 2012-01-19 Merck Canada Inc. Quinoline derivatives as EP4 antagonists
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
DOP2007000068A (es) 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
EP2013169B1 (en) 2006-04-24 2012-08-22 Merck Canada Inc. Indole amide derivatives as ep4 receptor antagonists
JP5183628B2 (ja) 2006-06-12 2013-04-17 メルク カナダ インコーポレイテッド Ｅｐ４受容体リガンドとしてのインドリンアミド誘導体
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
JP4960450B2 (ja) 2006-07-14 2012-06-27 ノバルティス アーゲー Ａｌｋ−５阻害剤としてのピリミジン誘導体
CA2660133C (en) 2006-08-11 2015-10-27 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
EP2114877B1 (en) 2007-02-26 2012-12-26 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
JP2010522218A (ja) 2007-03-26 2010-07-01 メルク フロスト カナダ リミテツド Ｅｐ４受容体アンタゴニストとしてのナフタレン及びキノリンスルホニル尿素誘導体
MX2009010297A (es) 2007-03-26 2009-10-12 Astellas Pharma Inc Derivado de ornitina.
EP2014657A1 (de) 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
WO2009005076A1 (ja) 2007-07-03 2009-01-08 Astellas Pharma Inc. アミド化合物
SI2212297T1 (sl) 2007-10-12 2011-09-30 Ingenium Pharmaceuticals Gmbh Inhibitorji protein kinaz
US8598202B2 (en) 2008-02-19 2013-12-03 Janssen Pharmaceutica Nv Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
PT2565191E (pt) 2008-05-14 2014-12-04 Astellas Pharma Inc Derivados do ácido 4-(indol-7- ilcarbonilaminometil)ciclo-hexanocarboxílico como antagonistas de receptores ep4, úteis no tratamento de insuficiência renal crónica ou de nefropatia diabética
US20130225528A1 (en) 2008-05-21 2013-08-29 Ariad Pharmaceuticals, Inc. Phosphorus Derivatives as Kinase Inhibitors
JP5536773B2 (ja) 2008-08-14 2014-07-02 ベータ・ファーマ・カナダ・インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのヘテロ環式アミド誘導体
US9029414B2 (en) 2008-09-19 2015-05-12 Biotechnology Research Corporation Triterpenoid compounds and methods of use thereof
WO2010034110A1 (en) 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
WO2011063181A1 (en) 2009-11-23 2011-05-26 Lexicon Pharmaceuticals, Inc. Methods and assays for the treatment of irritable bowel syndrome
WO2011144742A1 (en) 2010-05-21 2011-11-24 Chemilia Ab Novel pyrimidine derivatives
AU2011305872B2 (en) 2010-09-21 2015-03-26 Eisai R&D Management Co., Ltd. Pharmaceutical composition
EP2623594B9 (en) 2010-09-29 2015-07-22 NB Health Laboratory Co. Ltd. Antibody against human prostaglandin e2 receptor ep4
MX2013005535A (es) 2010-11-17 2013-07-03 Novartis Ag Compuesto de 3- (amino-aril) -piridina.
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
ES2545110T3 (es) 2010-12-10 2015-09-08 Rottapharm Biotech S.R.L. Derivados de piridinamida como antagonistas del receptor EP4
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
AU2012230229A1 (en) 2011-03-24 2013-10-10 Noviga Research Ab Novel pyrimidine derivatives
WO2012149528A1 (en) 2011-04-29 2012-11-01 Exelixis, Inc. Inhibitors of inducible form of 6-phosphofructose-2-kinase
CA2839956A1 (en) 2011-06-20 2012-12-27 Emory University Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
PL2729445T3 (pl) 2011-07-04 2016-04-29 Rottapharm Biotech Srl Cykliczne pochodne aminowe jako antagoniści receptora EP4
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
SG10201704095UA (en) 2012-04-24 2017-06-29 Vertex Pharma Dna-pk inhibitors
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
JO3296B1 (ar) 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
EP2711364A1 (en) * 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
PE20151412A1 (es) 2012-11-27 2015-10-10 Thomas Helledays Stiftelse For Medicinsk Forskning Derivados de pirimidin-2,4-diamina para el tratamiento de cancer
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
EP3009426B1 (en) 2013-06-12 2018-05-02 Kaken Pharmaceutical Co., Ltd. 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
BR112016004194A8 (pt) 2013-09-04 2020-02-11 Bristol Myers Squibb Co compostos úteis como imunomoduladores
SG11201601682RA (en) 2013-09-06 2016-04-28 Aurigene Discovery Tech Ltd 1,2,4-oxadiazole derivatives as immunomodulators
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
RU2675270C2 (ru) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
TR201807411T4 (tr) 2013-10-17 2018-06-21 Vertex Pharma DNA-PK inhibitörleri.
AU2014366371B2 (en) 2013-12-17 2017-02-16 Eli Lilly And Company Dimethylbenzoic acid compounds
AU2014366361B2 (en) 2013-12-17 2017-04-20 Eli Lilly And Company Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
US10052332B2 (en) 2014-04-29 2018-08-21 Emory University Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
AU2015264102C1 (en) 2014-05-23 2020-10-08 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
CN106794181A (zh) 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
SG11201705628UA (en) 2015-01-09 2017-08-30 Ono Pharmaceutical Co Tricyclic spiro compound
CA2993312A1 (en) 2015-07-23 2017-01-26 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
BR112018007664B1 (pt) 2015-10-16 2023-12-19 Eisai R&D Management Co., Ltd Compostos antagonistas de ep4, composição compreendendo o composto e uso dos mesmos para tratar câncer
CR20180323A (es) * 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
JP7033583B2 (ja) 2016-07-13 2022-03-10 バーテックス ファーマシューティカルズ インコーポレイテッド ゲノム編集効率を高めるための方法、組成物及びキット
UA124748C2 (uk) 2017-05-18 2021-11-10 Ідорсія Фармасьютікалз Лтд N-заміщені індольні похідні
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
WO2018210987A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
DK3625228T3 (da) 2017-05-18 2021-10-11 Idorsia Pharmaceuticals Ltd Pyrimidinderivater som pge2-receptormodulatorer
CA3063788A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives

Also Published As

Publication number Publication date
US11241431B2 (en) 2022-02-08
DK3377483T3 (da) 2021-12-06
SI3377483T1 (sl) 2022-01-31
JP2021107417A (ja) 2021-07-29
WO2017085198A1 (en) 2017-05-26
CL2018001325A1 (es) 2018-08-10
MA43251A (fr) 2021-04-28
HUE056679T2 (hu) 2022-02-28
US20200289507A1 (en) 2020-09-17
BR112018010291B1 (pt) 2023-12-26
KR102352022B1 (ko) 2022-01-14
HRP20211678T1 (hr) 2022-03-04
CY1124913T1 (el) 2023-01-05
AU2016358242A1 (en) 2018-07-05
TWI719078B (zh) 2021-02-21
KR20180081810A (ko) 2018-07-17
EA201891179A1 (ru) 2018-11-30
EP3377483A1 (en) 2018-09-26
IL259424B (en) 2020-11-30
JP2018534328A (ja) 2018-11-22
BR112018010291A2 (pt) 2018-11-06
LT3377483T (lt) 2021-11-10
UA123441C2 (uk) 2021-04-07
CN108349949A (zh) 2018-07-31
MA43251B1 (fr) 2021-11-30
TWI754397B (zh) 2022-02-01
CA3002610C (en) 2022-03-15
CR20180323A (es) 2018-08-06
EP3377483B9 (en) 2022-08-03
EP3928836A1 (en) 2021-12-29
CN108349949B (zh) 2020-11-17
TW202120497A (zh) 2021-06-01
PE20181304A1 (es) 2018-08-09
PH12018501077B1 (en) 2019-01-28
US20220175775A1 (en) 2022-06-09
SA518391588B1 (ar) 2021-03-17
AU2016358242B2 (en) 2021-03-11
TW201726661A (zh) 2017-08-01
RS62598B1 (sr) 2021-12-31
MA55046A (fr) 2021-12-29
MY195888A (en) 2023-02-27
EA037953B1 (ru) 2021-06-11
JP7228618B2 (ja) 2023-02-24
SG11201803627XA (en) 2018-06-28
PT3377483T (pt) 2021-11-22
ES2897954T3 (es) 2022-03-03
EP3377483B1 (en) 2021-09-01
US12011444B2 (en) 2024-06-18
IL259424A (en) 2018-07-31
MX2018005268A (es) 2018-11-29
CA3002610A1 (en) 2017-05-26
PL3377483T3 (pl) 2022-01-31
PH12018501077A1 (en) 2019-01-28

Similar Documents

Publication Publication Date Title
CO2018005715A2 (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2
CL2020002866A1 (es) Compuestos de heteroaril tetracíclicos
CO2019010804A2 (es) Derivados de indol n–sustituidos
CL2019003274A1 (es) Derivados de pirimidina como moduladores del receptor de pge2.
GT201600085A (es) Composiciones y métodos para modular los receptores x farnesoides
CO2019010578A2 (es) Derivados de fenilo como moduladores del receptor de pge2
EA201490287A1 (ru) Новые замещенные производные индола в качестве модуляторов гамма-секретазы
CR20150045A (es) Inhibidores de hepatitis c
CL2019000169A1 (es) Derivados de piperidina.
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CO2017008156A2 (es) Derivados de 1-(4-(4-(pirimidin-5-il)tiazol-5-il)piperazin-1-il)etan-1-ona y análogos de piridina de los mismos como moduladores del receptor cxcr3, composiciones que los comprenden y métodos de elaboración
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
CL2020001817A1 (es) Moduladores del receptor c5a
CO2019008941A2 (es) Moduladores del receptor de estrógeno
CO2021010930A2 (es) Hidroxipiridoxazepinas como activadores de nrf2
CL2022000893A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
CL2021003348A1 (es) Derivados de piridin–3–ilo.
UY37084A (es) Derivados de indano y su uso en terapias
CL2023000970A1 (es) Espiro derivados de alfa-d-galactopiranosidos
UY35348A (es) Derivados de carbazol inhibidores del bromodominio y composiciones que los contienen
CR11790A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3